III期黑色素瘤患者真实世界辅助抗PD-1免疫检查点抑制与靶向治疗的长期随访
研究纳入2018年6月至2019年9月德国11个皮肤癌中心开始辅助PD-1或靶向治疗的589例III期黑色素瘤患者,随访4年。PD-1组48个月无复发生存率为42.9%,靶向治疗组为52.6%;在BRAF突变患者中,PD-1组复发率高于靶向治疗组(HR 1.57)。
要点
- PD-1组48个月无复发生存率为42.9%,靶向治疗组为52.6%。
- BRAF突变患者中PD-1组复发风险高于靶向治疗组(HR 1.57,95%CI 1.09-2.26)。
- PD-1组中既往宏观淋巴结转移者1年无复发生存率为58%,靶向治疗组为87%。
核心结论
- BRAF突变的PD-1治疗患者复发率明显高于靶向治疗患者。
- 快速复发尤其见于既往有宏观淋巴结转移的PD-1治疗患者。
- 治疗短于6个月对PD-1患者的无复发生存无负面影响,但对靶向治疗患者有负面影响。
研究设计与样本
- 真实世界研究,纳入2018年6月至2019年9月德国11个皮肤癌中心开始辅助PD-1或靶向治疗的589例III期黑色素瘤患者,随访4年。
- 终点为无复发生存、总生存和黑色素瘤特异性生存,采用Kaplan-Meier法、Cox比例风险模型、逆概率治疗加权和倾向评分匹配估计生存和校正风险比。
主要发现
- 所有PD-1患者48个月无复发生存率为42.9%(95%CI 38.5-47.8),靶向治疗患者为52.6%(95%CI 43.6-63.3)。
- BRAF突变患者中,PD-1组复发率高于靶向治疗组(HR 1.57,95%CI 1.09-2.26)。
- PD-1治疗的BRAF突变患者4年总生存率为80.8%(95%CI 73.6-88.7),靶向治疗患者为87.3%(95%CI 81.0-94.0)。
- 切除宏观淋巴结转移后开始辅助PD-1的患者快速复发风险较高(所有PD-1患者1年无复发生存率58%),靶向治疗患者为87%。
- 提前停药(治疗≤6个月 vs >6个月)后复发率在靶向治疗患者中较高(HR 1.47,95%CI 0.67-3.23),但在PD-1患者中无此现象(HR 1.07,95%CI 0.73-1.55)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adjuvant treatment with immune checkpoint inhibition (PD-1) and targeted therapy (TT) with BRAF + MEK inhibitors significantly improved recurrence-free survival (RFS) of patients with stage III melanoma. We investigated efficacy of adjuvant therapy with PD-1 or TT under real-world conditions. MATERIALS AND METHODS: A total of 589 patients with stage III melanoma who started adjuvant PD-1 or TT between June 2018 and September 2019 from 11 major German Dermatologic Cooperative Oncology Group skin cancer centers were followed for 4 years. End points were RFS, overall survival (OS), and melanoma-specific survival. Survival analyses and adjusted hazard ratios (HRs) were estimated with Kaplan-Meier and Cox proportional hazards model, inverse probability treatment weighting, and propensity score matching. RESULTS: RFS at 48 months was 42.9% (95% CI, 38.5 to 47.8) for all PD-1 patients and 52.6% (95% CI, 43.6 to 63.3) for TT patients. Among patients with BRAF mutation, rate of recurrence was higher for PD-1 compared with TT (HR, 1.57 [95% CI, 1.09 to 2.26]). OS at 4 years was 80.8% (95% CI, 73.6 to 88.7) for PD-1-treated patients with BRAF mutation and 87.3% (95% CI, 81.0 to 94.0) for TT patients. Patients starting adjuvant PD-1 after resection of macroscopic lymph node metastases had a higher risk of rapid recurrence (1-year RFS all PD-1 58%) compared with 87% in TT patients. Rate of recurrence after premature discontinuation (≤6 v >6 months treatment) was higher in TT patients (HR, 1.47 [95% CI, 0.67 to 3.23]), but not in PD-1 patients (HR, 1.07 [95% CI, 0.73 to 1.55]). CONCLUSION: PD-1-treated patients with BRAF mutation had a markedly higher rate of relapse compared with TT patients. Rapid recurrences occurred particularly in PD-1-treated patients with previous macroscopic lymph node metastasis. Treatment duration shorter than 6 months did not negatively affect RFS in PD-1, but in TT patients.
引用
- Lodde GC, Hassel JC, von Wasielewski I, et al. Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma. J Clin Oncol. 2025. PMID: 40460331. doi:10.1200/JCO-24-02776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。